iX Biopharma secures Canadian patent for WaferiX

SINGAPORE (Oct 31): iX Biopharma announced that it has secured a Canadian patent for its WaferiX drug delivery technology.

The Canadian patent will expire on 26 Oct 2030, and marks a milestone for the pharmaceutical company after its positive results for its bioequivalene study for PheoniX, a drug for treating male erectile dysfunction.

In its SGX filing, the company stated that it has also been granted a patent in South Korea, while counter patents were granted in Australia, Indonesia, Japan, Malaysia, New Zealand and Singapore prior to that.

---

Related Stories

• Australia’s social media ban for under 16s to become law
• Can SGX afford to wait up to a year for reforms?
• Key issues Khazanah-led consortium will have to fix at MAHB post-privatisation

---